A pilot study of blood epinephrine levels and CREB phosphorylation in men undergoing prostate biopsies

PurposeIn mouse models of prostate cancer, increased epinephrine levels accelerated tumor growth via the beta2-adrenoreceptor/PKA signaling pathway. It is unknown, however, whether men experience increased epinephrine levels sufficient to activate the beta2-adrenoreceptor/PKA pathway in the prostate gland. We measured epinephrine levels in blood samples collected immediately prior to prostate biopsies and measured phosphorylation of S133CREB (PKA site), S112BAD, T202/Y204ERK, and S473 Akt in prostate biopsy tissue samples.MethodsTissue samples and 3 ml of blood were obtained from men (n = 20) recruited from the patients scheduled for prostate biopsies. Epinephrine levels were measured by ELISA. Proteins were extracted from biopsied tissue, and protein phosphorylation was measured by Western blotting with phospho-specific antibodies. Pearson and Spearman’s rank correlations were analyzed to assess relationships between blood epinephrine levels and phosphorylation of CREB, BAD, AKT, and ERK.ResultsEpinephrine levels above 1 nM were detected in 5 of 20 patients. A strong positive correlation was observed between increased epinephrine levels and CREB phosphorylation. In contrast, no correlation was observed between epinephrine levels and phosphorylation of ERK, BAD, or AKT.ConclusionOur results suggest that increased blood epinephrine levels activate the beta2-adrenoreceptor/PKA signaling pathway in human prostate glands. These results will inform future studies to examine whether beta2-selective blockers can inhibit activation of the epinephrine/ADRB2/PKA pathway in prostate tumors of men with increased epinephrine levels and explore the use of beta2-selective blockers as adjuvant therapy for prostate cancer.

[1]  P. Schnohr,et al.  Sociodemographic status, stress, and risk of prostate cancer. A prospective cohort study. , 2007, Annals of epidemiology.

[2]  Sandeep Robert Datta,et al.  Behavioral stress accelerates prostate cancer development in mice. , 2013, The Journal of clinical investigation.

[3]  I. Bairati,et al.  Antihypertensive Drug Use and The Risk of Prostate Cancer (Canada) , 2004, Cancer Causes & Control.

[4]  David Spiegel,et al.  Depression and cancer: mechanisms and disease progression , 2003, Biological Psychiatry.

[5]  P. Casey,et al.  Androgen Receptor Activation by Gs Signaling in Prostate Cancer Cells* , 2005, Journal of Biological Chemistry.

[6]  Sandeep Robert Datta,et al.  Diverse Antiapoptotic Signaling Pathways Activated by Vasoactive Intestinal Polypeptide, Epidermal Growth Factor, and Phosphatidylinositol 3-Kinase in Prostate Cancer Cells Converge on BAD* , 2006, Journal of Biological Chemistry.

[7]  N. Schneiderman,et al.  Illness perceptions and emotional well-being in men treated for localized prostate cancer. , 2009, Journal of psychosomatic research.

[8]  D. Meltzer,et al.  The role of anxiety in prostate carcinoma , 2005, Cancer.

[9]  G. Friedman,et al.  Norepinephrine antagonists and cancer risk , 2011, International journal of cancer.

[10]  David B Jackson,et al.  Src activation by β-adrenoreceptors is a key switch for tumor metastasis , 2012, Nature Communications.

[11]  D. Pasco,et al.  Evaluation of β-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP , 2003 .

[12]  D. Cook,et al.  Does β-adrenoceptor blocker therapy improve cancer survival? Findings from a population-based retrospective cohort study. , 2011, British journal of clinical pharmacology.

[13]  David B Jackson,et al.  Src activation by b-adrenoreceptors is a key switch for tumour metastasis , 2013 .

[14]  S. Lutgendorf,et al.  Cancer fear and mood disturbance after radical prostatectomy: consequences of biochemical evidence of recurrence. , 2003, The Journal of urology.

[15]  D. Pasco,et al.  Evaluation of beta-adrenergic receptor subtypes in the human prostate cancer cell line-LNCaP. , 2003, Biochemical pharmacology.

[16]  Morten Wang Fagerland,et al.  Use of β‐blockers is associated with prostate cancer‐specific survival in prostate cancer patients on androgen deprivation therapy , 2013, The Prostate.

[17]  George Kulik,et al.  Epinephrine Protects Cancer Cells from Apoptosis via Activation of cAMP-dependent Protein Kinase and BAD Phosphorylation* , 2007, Journal of Biological Chemistry.

[18]  G. Davey Smith,et al.  The role of self-reported stress in the development of breast cancer and prostate cancer: a prospective cohort study of employed males and females with 30 years of follow-up. , 2007, European journal of cancer.

[19]  Luis Mateus Rocha,et al.  Psychoneuroendocrinological and immunological parameters in cancer patients: Involvement of stress and depression , 1990, Psychoneuroendocrinology.

[20]  V. Preedy,et al.  Prospective Cohort Study , 2010 .

[21]  A. Shaywitz,et al.  CREB: a stimulus-induced transcription factor activated by a diverse array of extracellular signals. , 1999, Annual review of biochemistry.

[22]  S. Madersbacher,et al.  Endocrine patterns in patients with benign and malignant prostatic diseases , 2000, The Prostate.

[23]  T. L. Drell,et al.  The norepinephrine‐driven metastasis development of PC‐3 human prostate cancer cells in BALB/c nude mice is inhibited by β‐blockers , 2006, International journal of cancer.

[24]  Steve W. Cole,et al.  Neuroendocrine modulation of cancer progression , 2009, Brain, Behavior, and Immunity.

[25]  M. Sadar.  Androgen-independent Induction of Prostate-specific Antigen Gene Expression via Cross-talk between the Androgen Receptor and Protein Kinase A Signal Transduction Pathways* , 1999, The Journal of Biological Chemistry.